The host explains what amylin is and why pairing it with semaglutide matters, framing it as an evidence-based primer.
Recap by typeshit. Post by Facebook on Facebook.
The review looks at concerns about misuse as demand for GLP-1 drugs grows, and points to how little evidence guides their use beyond approved conditions.
Researchers found self-reported GLP-1 use climbed from March 2024 to October 2025, mostly for weight loss, through channels insurance data may not capture.
The study is looking for women with hot flashes and night sweats and a BMI above 30. Mayo Clinic has the full eligibility rules and how to sign up.
A matched cohort study in Inflammatory Bowel Diseases found remission odds nearly six times higher on GLP-1 drugs, and weight loss alone didn't explain it.
The Saudi Food & Drug Authority stresses that retatrutide hasn't been cleared yet, as unapproved versions keep circulating.
The Wegovy maker wants the federal government to show more ambition and open a quick, practical route to affordable treatment for patients.
Loading…